{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:09:50Z","timestamp":1761808190845,"version":"3.37.3"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,6,11]],"date-time":"2018-06-11T00:00:00Z","timestamp":1528675200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Postdoctoral Scientific Research Developmental Fund of  Heilongjiang Postdoctoral Program, China","award":["No. LBH-Q16143"],"award-info":[{"award-number":["No. LBH-Q16143"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s12094-018-1906-4","type":"journal-article","created":{"date-parts":[[2018,6,11]],"date-time":"2018-06-11T04:04:24Z","timestamp":1528689864000},"page":"197-205","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Differential molecular markers of primary lung tumors and metastatic sites indicate different possible treatment selections in patients with metastatic lung adenocarcinoma"],"prefix":"10.1007","volume":"21","author":[{"given":"L.-L.","family":"Deng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.-B.","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.-L.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3785-8663","authenticated-orcid":false,"given":"Y.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,11]]},"reference":[{"issue":"1","key":"1906_CR1","doi-asserted-by":"publisher","first-page":"11119","DOI":"10.1038\/s41598-017-11520-6","volume":"7","author":"N An","year":"2017","unstructured":"An N, Yang X. Identification of prognostic genes through expression differentiation during metastatic process in lung adenocarcinoma. Sci Rep. 2017;7(1):11119. \n                    https:\/\/doi.org\/10.1038\/s41598-017-11520-6\n                    \n                  .","journal-title":"Sci Rep"},{"issue":"11","key":"1906_CR2","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1080\/15384047.2016.1235660","volume":"18","author":"Z Song","year":"2017","unstructured":"Song Z, Yu X, Zhang Y. Clinicopathological characteristics and survival of ALK, ROS1 and RET rearrangements in non-adenocarcinoma non-small cell lung cancer patients. Cancer Biol Ther. 2017;18(11):883\u20137. \n                    https:\/\/doi.org\/10.1080\/15384047.2016.1235660\n                    \n                  .","journal-title":"Cancer Biol Ther"},{"issue":"1","key":"1906_CR3","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1186\/s12885-016-2902-0","volume":"16","author":"R Ko","year":"2016","unstructured":"Ko R, Kenmotsu H, Serizawa M, Koh Y, Wakuda K, Ono A, et al. Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients. BMC Cancer. 2016;16(1):864. \n                    https:\/\/doi.org\/10.1186\/s12885-016-2902-0\n                    \n                  .","journal-title":"BMC Cancer"},{"key":"1906_CR4","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.lungcan.2016.11.022","volume":"104","author":"YL Wu","year":"2017","unstructured":"Wu YL, Saijo N, Thongprasert S, Yang JC, Han B, Margono B, et al. Efficacy according to blind independent central review: post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin\/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC. Lung Cancer. 2017;104:119\u201325. \n                    https:\/\/doi.org\/10.1016\/j.lungcan.2016.11.022\n                    \n                  .","journal-title":"Lung Cancer"},{"issue":"5","key":"1906_CR5","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1200\/JCO.2009.24.3030","volume":"28","author":"JY Douillard","year":"2010","unstructured":"Douillard JY, Shepherd FA, Hirsh V, Mok T, Socinski MA, Gervais R, et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol. 2010;28(5):744\u201352. \n                    https:\/\/doi.org\/10.1200\/JCO.2009.24.3030\n                    \n                  .","journal-title":"J Clin Oncol"},{"issue":"11","key":"1906_CR6","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1097\/JTO.0000000000000344","volume":"9","author":"AM Litvak","year":"2014","unstructured":"Litvak AM, Paik PK, Woo KM, Sima CS, Hellmann MD, Arcila ME, et al. Clinical characteristics and course of 63 patients with BRAF mutant lung cancers. J Thorac Oncol. 2014;9(11):1669\u201374. \n                    https:\/\/doi.org\/10.1097\/JTO.0000000000000344\n                    \n                  .","journal-title":"J Thorac Oncol"},{"issue":"1","key":"1906_CR7","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13000-016-0544-9","volume":"11","author":"L Brcic","year":"2016","unstructured":"Brcic L, Jakopovic M, Misic M, Seiwerth F, Kern I, Smojver-Jezek S, et al. Analysis of the frequency of EGFR, KRAS and ALK mutations in patients with lung adenocarcinoma in Croatia. Diagn Pathol. 2016;11(1):90. \n                    https:\/\/doi.org\/10.1186\/s13000-016-0544-9\n                    \n                  .","journal-title":"Diagn Pathol"},{"key":"1906_CR8","doi-asserted-by":"publisher","first-page":"39721","DOI":"10.1038\/srep39721","volume":"7","author":"Z Lohinai","year":"2017","unstructured":"Lohinai Z, Klikovits T, Moldvay J, Ostoros G, Raso E, Timar J, et al. KRAS-mutation incidence and prognostic value are metastatic site-specific in lung adenocarcinoma: poor prognosis in patients with KRAS mutation and bone metastasis. Sci Rep. 2017;7:39721. \n                    https:\/\/doi.org\/10.1038\/srep39721\n                    \n                  .","journal-title":"Sci Rep"},{"issue":"26","key":"1906_CR9","doi-asserted-by":"publisher","first-page":"4268","DOI":"10.1200\/JCO.2007.14.8924","volume":"26","author":"CQ Zhu","year":"2008","unstructured":"Zhu CQ, da Cunha Santos G, Ding K, Sakurada A, Cutz JC, Liu N, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol. 2008;26(26):4268\u201375. \n                    https:\/\/doi.org\/10.1200\/jco.2007.14.8924\n                    \n                  .","journal-title":"J Clin Oncol"},{"issue":"25","key":"1906_CR10","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1056\/NEJMoa043623","volume":"352","author":"T Winton","year":"2005","unstructured":"Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005;352(25):2589\u201397. \n                    https:\/\/doi.org\/10.1056\/NEJMoa043623\n                    \n                  .","journal-title":"N Engl J Med"},{"issue":"10","key":"1906_CR11","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.1002\/cam4.852","volume":"5","author":"Z Song","year":"2016","unstructured":"Song Z, Yu X, Zhang Y. Mutation and prognostic analyses of PIK3CA in patients with completely resected lung adenocarcinoma. Cancer Med. 2016;5(10):2694\u2013700. \n                    https:\/\/doi.org\/10.1002\/cam4.852\n                    \n                  .","journal-title":"Cancer Med"},{"issue":"7","key":"1906_CR12","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s12032-014-0058-9","volume":"31","author":"LM Sad","year":"2014","unstructured":"Sad LM, Younis SG, Elity MM. Prognostic and predictive role of ERCC1 protein expression in locally advanced stage III non-small cell lung cancer. Med Oncol. 2014;31(7):58. \n                    https:\/\/doi.org\/10.1007\/s12032-014-0058-9\n                    \n                  .","journal-title":"Med Oncol"},{"issue":"12","key":"1906_CR13","doi-asserted-by":"publisher","first-page":"12679","DOI":"10.1007\/s13277-014-2592-7","volume":"35","author":"H Zhao","year":"2014","unstructured":"Zhao H, Zhang H, Du Y, Gu X. Prognostic significance of BRCA1, ERCC1, RRM1, and RRM2 in patients with advanced non-small cell lung cancer receiving chemotherapy. Tumour Biol. 2014;35(12):12679\u201388. \n                    https:\/\/doi.org\/10.1007\/s13277-014-2592-7\n                    \n                  .","journal-title":"Tumour Biol"},{"issue":"5","key":"1906_CR14","doi-asserted-by":"publisher","first-page":"3523","DOI":"10.3892\/mmr.2014.3141","volume":"11","author":"H Jiang","year":"2015","unstructured":"Jiang H, Wang H, Wang S, Pei Z, Fu Z, Fang C, et al. Expression of ERCC1, TYMS, RRM1, TUBB3, non-muscle myosin II, myoglobin and MyoD1 in lung adenocarcinoma pleural effusions predicts survival in patients receiving platinum-based chemotherapy. Mol Med Rep. 2015;11(5):3523\u201332. \n                    https:\/\/doi.org\/10.3892\/mmr.2014.3141\n                    \n                  .","journal-title":"Mol Med Rep"},{"issue":"3","key":"1906_CR15","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.lungcan.2009.07.004","volume":"68","author":"CH Kang","year":"2010","unstructured":"Kang CH, Jang BG, Kim DW, Chung DH, Kim YT, Jheon S, et al. The prognostic significance of ERCC1, BRCA1, XRCC1, and betaIII-tubulin expression in patients with non-small cell lung cancer treated by platinum- and taxane-based neoadjuvant chemotherapy and surgical resection. Lung Cancer. 2010;68(3):478\u201383. \n                    https:\/\/doi.org\/10.1016\/j.lungcan.2009.07.004\n                    \n                  .","journal-title":"Lung Cancer"},{"issue":"6","key":"1906_CR16","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1158\/0008-5472.CAN-09-2533","volume":"70","author":"PG Nikolinakos","year":"2010","unstructured":"Nikolinakos PG, Altorki N, Yankelevitz D, Tran HT, Yan S, Rajagopalan D, et al. Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib. Cancer Res. 2010;70(6):2171\u20139. \n                    https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-2533\n                    \n                  .","journal-title":"Cancer Res"},{"issue":"13","key":"1906_CR17","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.1245\/s10434-017-6083-0","volume":"24","author":"P Bao","year":"2017","unstructured":"Bao P, Yokobori T, Altan B, Iijima M, Azuma Y, Onozato R, et al. High STMN1 expression is associated with cancer progression and chemo-resistance in lung squamous cell carcinoma. Ann Surg Oncol. 2017;24(13):4017\u201324. \n                    https:\/\/doi.org\/10.1245\/s10434-017-6083-0\n                    \n                  .","journal-title":"Ann Surg Oncol"},{"issue":"Supplement","key":"1906_CR18","doi-asserted-by":"publisher","first-page":"S72","DOI":"10.4103\/0973-1482.172108","volume":"14","author":"TL Wang","year":"2018","unstructured":"Wang TL, Song YQ, Ren YW, Zhou BS, Wang HT, Gao Y, et al. Dual-specificity phosphatase 6 genetic variants associated with risk of lung squamous cell carcinoma in Han Chinese. J Cancer Res Ther. 2018;14(Supplement):S72\u20138. \n                    https:\/\/doi.org\/10.4103\/0973-1482.172108\n                    \n                  .","journal-title":"J Cancer Res Ther"},{"issue":"12","key":"1906_CR19","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1007\/s00432-014-1751-y","volume":"140","author":"LL Deng","year":"2014","unstructured":"Deng LL, Deng HB, Lu CL, Guo Y, Wang D, Yan CH, et al. Mutations of EGFR or KRAS and expression of chemotherapy-related genes based on small biopsy samples in stage IIIB and IV inoperable non-small cell lung cancer. J Cancer Res Clin Oncol. 2014;140(12):2097\u2013105. \n                    https:\/\/doi.org\/10.1007\/s00432-014-1751-y\n                    \n                  .","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"1906_CR20","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12916-017-0900-y","volume":"15","author":"DR Caswell","year":"2017","unstructured":"Caswell DR, Swanton C. The role of tumour heterogeneity and clonal cooperativity in metastasis, immune evasion and clinical outcome. BMC Med. 2017;15(1):133. \n                    https:\/\/doi.org\/10.1186\/s12916-017-0900-y\n                    \n                  .","journal-title":"BMC Med"},{"issue":"8","key":"1906_CR21","doi-asserted-by":"publisher","first-page":"161007","DOI":"10.1098\/rsos.161007","volume":"4","author":"A Hallou","year":"2017","unstructured":"Hallou A, Jennings J, Kabla AJ. Tumour heterogeneity promotes collective invasion and cancer metastatic dissemination. R Soc Open Sci. 2017;4(8):161007. \n                    https:\/\/doi.org\/10.1098\/rsos.161007\n                    \n                  .","journal-title":"R Soc Open Sci"},{"issue":"5","key":"1906_CR22","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.jtho.2016.01.025","volume":"11","author":"FC Detterbeck","year":"2016","unstructured":"Detterbeck FC, Franklin WA, Nicholson AG, Girard N, Arenberg DA, Travis WD, et al. The IASLC lung cancer staging project: background data and proposed criteria to distinguish separate primary lung cancers from metastatic foci in patients with two lung tumors in the forthcoming eighth edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11(5):651\u201365. \n                    https:\/\/doi.org\/10.1016\/j.jtho.2016.01.025\n                    \n                  .","journal-title":"J Thorac Oncol"},{"key":"1906_CR23","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s12885-016-2249-6","volume":"16","author":"G Quere","year":"2016","unstructured":"Quere G, Descourt R, Robinet G, Autret S, Raguenes O, Fercot B, et al. Mutational status of synchronous and metachronous tumor samples in patients with metastatic non-small-cell lung cancer. BMC Cancer. 2016;16:210. \n                    https:\/\/doi.org\/10.1186\/s12885-016-2249-6\n                    \n                  .","journal-title":"BMC Cancer"},{"issue":"7","key":"1906_CR24","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.jtho.2017.04.011","volume":"12","author":"K Chansky","year":"2017","unstructured":"Chansky K, Detterbeck FC, Nicholson AG, Rusch VW, Vallieres E, Groome P, et al. The IASLC lung cancer staging project: external validation of the revision of the TNM stage groupings in the eighth edition of the TNM classification of lung cancer. J Thorac Oncol. 2017;12(7):1109\u201321. \n                    https:\/\/doi.org\/10.1016\/j.jtho.2017.04.011\n                    \n                  .","journal-title":"J Thorac Oncol"},{"issue":"11S","key":"1906_CR25","doi-asserted-by":"publisher","first-page":"S273","DOI":"10.1016\/j.jtho.2016.09.042","volume":"11","author":"X Niu","year":"2016","unstructured":"Niu X, Ai X, Chen Z, Chuai S, Yang Y, Lu S. Tumor heterogeneity in lesion specific response creates ROS1 fusion mediating resistance to gefitinib in EGFR 19 deletion lung adenocarcinoma: topic\u2014medical oncology. J Thorac Oncol. 2016;11(11S):S273. \n                    https:\/\/doi.org\/10.1016\/j.jtho.2016.09.042\n                    \n                  .","journal-title":"J Thorac Oncol"},{"issue":"1","key":"1906_CR26","doi-asserted-by":"publisher","first-page":"5593","DOI":"10.1038\/s41598-017-05642-0","volume":"7","author":"LM Tan","year":"2017","unstructured":"Tan LM, Qiu CF, Zhu T, Jin YX, Li X, Yin JY, et al. Genetic polymorphisms and platinum-based chemotherapy treatment outcomes in patients with non-small cell lung cancer: a genetic epidemiology study based meta-analysis. Sci Rep. 2017;7(1):5593. \n                    https:\/\/doi.org\/10.1038\/s41598-017-05642-0\n                    \n                  .","journal-title":"Sci Rep"},{"issue":"4","key":"1906_CR27","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1200\/JCO.2016.68.1841","volume":"35","author":"SM Lee","year":"2017","unstructured":"Lee SM, Falzon M, Blackhall F, Spicer J, Nicolson M, Chaudhuri A, et al. Randomized prospective biomarker trial of ERCC1 for comparing platinum and nonplatinum therapy in advanced non-small-cell lung cancer: ERCC1 trial (ET). J Clin Oncol. 2017;35(4):402\u201311. \n                    https:\/\/doi.org\/10.1200\/JCO.2016.68.1841\n                    \n                  .","journal-title":"J Clin Oncol"},{"issue":"9","key":"1906_CR28","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/j.humpath.2011.08.018","volume":"43","author":"WE Pierceall","year":"2012","unstructured":"Pierceall WE, Sprott KM, Heikkinen T, Heikkila P, Alaparthi L, Aittomaki K, et al. Utilization of fluorescence in situ hybridization with cytokeratin discriminators in TOP2A assessment of chemotherapy-treated patients with breast cancer. Hum Pathol. 2012;43(9):1363\u201375. \n                    https:\/\/doi.org\/10.1016\/j.humpath.2011.08.018\n                    \n                  .","journal-title":"Hum Pathol"},{"issue":"26","key":"1906_CR29","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1200\/JCO.2011.35.9638","volume":"29","author":"A Marchetti","year":"2011","unstructured":"Marchetti A, Felicioni L, Malatesta S, Grazia Sciarrotta M, Guetti L, Chella A, et al. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol. 2011;29(26):3574\u20139. \n                    https:\/\/doi.org\/10.1200\/JCO.2011.35.9638\n                    \n                  .","journal-title":"J Clin Oncol"},{"issue":"50","key":"1906_CR30","doi-asserted-by":"publisher","first-page":"e5601","DOI":"10.1097\/MD.0000000000005601","volume":"95","author":"N An","year":"2016","unstructured":"An N, Zhang Y, Niu H, Li Z, Cai J, Zhao Q, et al. EGFR-TKIs versus taxanes agents in therapy for non-small-cell lung cancer patients: a PRISMA-compliant systematic review with meta-analysis and meta-regression. Medicine (Baltimore). 2016;95(50):e5601. \n                    https:\/\/doi.org\/10.1097\/MD.0000000000005601\n                    \n                  .","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"1906_CR31","doi-asserted-by":"publisher","first-page":"77","DOI":"10.21037\/cco.2016.11.02","volume":"5","author":"S Hirano","year":"2016","unstructured":"Hirano S, Naka G, Takeda Y, Iikura M, Hayama N, Yanagisawa A, et al. A prospective, multicenter phase II trial of low-dose erlotinib as maintenance treatment after platinum doublet chemotherapy for advanced non-small cell lung cancer harboring EGFR mutation. Chin Clin Oncol. 2016;5(6):77. \n                    https:\/\/doi.org\/10.21037\/cco.2016.11.02\n                    \n                  .","journal-title":"Chin Clin Oncol"},{"issue":"1","key":"1906_CR32","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1097\/COC.0b013e318287bb23","volume":"38","author":"AD Campos-Parra","year":"2015","unstructured":"Campos-Parra AD, Zuloaga C, Manriquez ME, Aviles A, Borbolla-Escoboza J, Cardona A, et al. KRAS mutation as the biomarker of response to chemotherapy and EGFR-TKIs in patients with advanced non-small cell lung cancer: clues for its potential use in second-line therapy decision making. Am J Clin Oncol. 2015;38(1):33\u201340. \n                    https:\/\/doi.org\/10.1097\/COC.0b013e318287bb23\n                    \n                  .","journal-title":"Am J Clin Oncol"},{"issue":"3","key":"1906_CR33","doi-asserted-by":"publisher","first-page":"e0174515","DOI":"10.1371\/journal.pone.0174515","volume":"12","author":"GX Hou","year":"2017","unstructured":"Hou GX, Liu P, Yang J, Wen S. Mining expression and prognosis of topoisomerase isoforms in non-small-cell lung cancer by using Oncomine and Kaplan\u2013Meier plotter. PLoS One. 2017;12(3):e0174515. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0174515\n                    \n                  .","journal-title":"PLoS One"},{"issue":"4","key":"1906_CR34","doi-asserted-by":"publisher","first-page":"322","DOI":"10.5114\/wo.2012.30061","volume":"16","author":"G Kaczmarczyk","year":"2012","unstructured":"Kaczmarczyk G, Lewandowski R, Trautsolt W, Ziolkowski A, Kozielski J. Cytological examination of pleural cavity lavage accompanied by the study of gene promoter hypermethylation of p16 and O6-methylguanine-DNA-methyltransferase genes in diagnostics of non-small cell lung cancer metastatic changes into pleura. Contemp Oncol (Pozn). 2012;16(4):322\u20137. \n                    https:\/\/doi.org\/10.5114\/wo.2012.30061\n                    \n                  .","journal-title":"Contemp Oncol (Pozn)"},{"key":"1906_CR35","doi-asserted-by":"publisher","first-page":"7297","DOI":"10.2147\/OTT.S111291","volume":"9","author":"J Zhang","year":"2016","unstructured":"Zhang J, Fu J, Pan Y, Zhang X, Shen L. Silencing of miR-1247 by DNA methylation promoted non-small-cell lung cancer cell invasion and migration by effects of STMN1. Oncol Targets Ther. 2016;9:7297\u2013307. \n                    https:\/\/doi.org\/10.2147\/OTT.S111291\n                    \n                  .","journal-title":"Oncol Targets Ther"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12094-018-1906-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-018-1906-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-018-1906-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,9]],"date-time":"2019-09-09T11:06:37Z","timestamp":1568027197000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12094-018-1906-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,11]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["1906"],"URL":"https:\/\/doi.org\/10.1007\/s12094-018-1906-4","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"type":"print","value":"1699-048X"},{"type":"electronic","value":"1699-3055"}],"subject":[],"published":{"date-parts":[[2018,6,11]]},"assertion":[{"value":"27 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declared that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the Ethical Review Committee of Second Affiliated Hospital of Harbin Medical University and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. For this retrospective study formal consent is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}